A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous ...

For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as scientifically valid. The Committee for Medicinal Products for Human Use ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...

There are ongoing shortages of 34 medicines, according to the European Medicines Agency (EMA). Sixteen of those are on the EU’s list of essential drugs that the European Commission aims to ...

Myanmar's devastating earthquake has worsened an already dire humanitarian crisis, with thousands dead, displaced, and in ...

The European Commission has proposed new rules aimed at strengthening the security of supply and availability of critical medicines, prioritising EU-based suppliers in public procurement. View on euro ...

Jefferies analyst Michael Yee initiated coverage of Blueprint Medicines (BPMC) with a Buy rating and $135 price target The firm finds the stock “quite attractive,” especially on the recent ...

QUEZON CITY, (PIA) — As the popularity of alternative medicines grows, experts are cautioning consumers ... ng Masa” teleradyo program organized by the Philippine Information Agency, Dr. Ma. Teresa ...

This funding will likely only cover the coordination efforts of the European Medicines Agency (EMA) and the European Commission, rather than supporting large-scale production shifts. While strategic ...

European leaders are seeking to contain the damage from President Trump and Ukraine's President Zelenskyy’s Oval Office clash, with Britain declaring a coalition of the willing with money and ...

Morgan Stanley analyst Judah Frommer assumed coverage of Blueprint Medicines (BPMC) with an Equal Weight rating and price target of $100, down from $120. The firm sees Ayvakit ramping to a $2B ...

Arne Dedert / picture alliance via Getty Images European equities have this year outperformed U.S. stocks by the widest margin since 2000, according to a recent report from Morgan Stanley.